Johnson & Johnson omits 2 deaths in study of Natrecor

Johnson & Johnson said this week that two more patients died after taking its Natrecor heart failure drug than the company had reported in October. The two deaths were omitted in a report on a study published in the Oct. 2005 issue of The Journal of Emergency Medicine. J&J said in a statement that it is in the process of finalizing an audit of the data. Upon completion, it will reanalyze the data to see if it makes a statistically significant difference in the drug’s risk. Natrecor is manufactured by J&J’s Scios unit and was approved in 2001. The FDA told Scios early last year to analyze further the study data for mortality. J&J plans a final report by the end of March.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.